The evolution of antiandrogens: MDV3100 comes of age

Lucy Dumas; Heather Payne; Simon Chowdhury

doi:10.1586/ERA.11.210

The evolution of antiandrogens: MDV3100 comes of age

Lucy Dumas, Heather Payne, Simon Chowdhury^*

^*Corresponding author for this work

King's College London

Research output: Contribution to journal › Editorial › peer-review

8 Citations (Scopus)

Original language	English
Pages (from-to)	131-133
Number of pages	3
Journal	EXPERT REVIEW OF ANTICANCER THERAPY
Volume	12
Issue number	2
DOIs	https://doi.org/10.1586/ERA.11.210
Publication status	Published - Feb 2012

Keywords

abiraterone
castrate refractory
MDV3100
prostate cancer
ADVANCED PROSTATE-CANCER
CASTRATION
MONOTHERAPY

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1586/ERA.11.210

Cite this

@article{1d454e12ceed422e9650b049dcaf73c4,

title = "The evolution of antiandrogens: MDV3100 comes of age",

keywords = "abiraterone, castrate refractory, MDV3100, prostate cancer, ADVANCED PROSTATE-CANCER, CASTRATION, MONOTHERAPY",

author = "Lucy Dumas and Heather Payne and Simon Chowdhury",

year = "2012",

month = feb,

doi = "10.1586/ERA.11.210",

language = "English",

volume = "12",

pages = "131--133",

journal = "EXPERT REVIEW OF ANTICANCER THERAPY",

issn = "1473-7140",

publisher = "Expert Reviews Ltd.",

number = "2",

}

TY - JOUR

T1 - The evolution of antiandrogens

T2 - MDV3100 comes of age

AU - Dumas, Lucy

AU - Payne, Heather

AU - Chowdhury, Simon

PY - 2012/2

Y1 - 2012/2

KW - abiraterone

KW - castrate refractory

KW - MDV3100

KW - prostate cancer

KW - ADVANCED PROSTATE-CANCER

KW - CASTRATION

KW - MONOTHERAPY

U2 - 10.1586/ERA.11.210

DO - 10.1586/ERA.11.210

M3 - Editorial

SN - 1473-7140

VL - 12

SP - 131

EP - 133

JO - EXPERT REVIEW OF ANTICANCER THERAPY

JF - EXPERT REVIEW OF ANTICANCER THERAPY

IS - 2

ER -